home / stock / ghrs / ghrs news


GHRS News and Press, GH Research PLC From 11/09/23

Stock Information

Company Name: GH Research PLC
Stock Symbol: GHRS
Market: NASDAQ
Website: ghres.com

Menu

GHRS GHRS Quote GHRS Short GHRS News GHRS Articles GHRS Message Board
Get GHRS Alerts

News, Short Squeeze, Breakout and More Instantly...

GHRS - GH Research Reports Third Quarter Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and pro...

GHRS - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

GHRS - Expected earnings - GH Research PLC

GH Research PLC (GHRS) is expected to report $-0.2 for Q3 2023

GHRS - GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its ...

GHRS - With ecstasy a potential PTSD therapy, psychedelic treatments could take off

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

GHRS - Psilocybin in depression: study shows lasting benefit

2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...

GHRS - GH Research Non-GAAP EPS of -$0.15

2023-08-23 15:24:11 ET GH Research press release ( NASDAQ: GHRS ): Q2 Non-GAAP EPS of -$0.15. Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023. For further details see: GH Research Non-GAAP EPS of -$...

GHRS - GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided...

GHRS - Psychedelic therapy should be done in conjunction with psychotherapy - group

2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...

GHRS - President Biden is 'very open-minded' about psychedelics, younger brother says

2023-06-29 12:54:19 ET President Joe Biden is very "open-minded about" psychedelic medications, his youngest brother Frank Biden said during an interview on Wednesday, recalling a conversation the siblings had about the psychoactive substances. "He is very open-minded," the younger Bide...

Previous 10 Next 10